201. Effectiveness of COVID-19 Vaccines over 13 Months Covering the Period of the Emergence of the Omicron Variant in the Swedish Population
- Author
-
Xu, Yiyi, Li, Huiqi, Kirui, Brian, Santosa, Ailiana, Gisslen, Magnus, Leach, Susannah, Wettermark, Björn, Vanfleteren, Lowie E. G. W., Nyberg, Fredrik, Xu, Yiyi, Li, Huiqi, Kirui, Brian, Santosa, Ailiana, Gisslen, Magnus, Leach, Susannah, Wettermark, Björn, Vanfleteren, Lowie E. G. W., and Nyberg, Fredrik
- Abstract
Background: We estimated real-world vaccine effectiveness (VE) against COVID-19 infection, hospitalization, ICU admission, and death up to 13 months after vaccination. VE before and after the emergence of Omicron was investigated. Methods: We used registered data from the entire Swedish population above age 12 (n = 9,153,456). Cox regression with time-varying exposure was used to estimate weekly/monthly VE against COVID-19 outcomes from 27 December 2020 to 31 January 2022. The analyses were stratified by age, sex, and vaccine type (BNT162b2, mRNA-1273, and AZD1222). Results: Two vaccine doses offered good long-lasting protection against infection before Omicron (VE were above 85% for all time intervals) but limited protection against Omicron infection (dropped to 43% by week four and no protection by week 14). For severe COVID-19 outcomes, higher VE was observed during the entire follow-up period. Among individuals above age 65, the mRNA vaccines showed better VE against infection than AZD1222 but similar high VE against hospitalization. Conclusions: Our findings provide strong evidence for long-term maintained protection against severe COVID-19 by the basic two-dose schedule, supporting more efforts to encourage unvaccinated persons to get the basic two doses, and encourage vaccinated persons to get a booster to ensure better population-level protection.
- Published
- 2022
- Full Text
- View/download PDF